{"id":"W3026866758","doi":"10.1016/j.annonc.2020.03.241","title":"140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Genentech; PharmaMar; Eisai; Daiichi-Sankyo; Invitae; Puma Biotechnology; Incyte; BeiGene; AbbVie; Daiichi Sankyo Europe; U.S. Department of Defense; Sanofi; Cilag; Celldex Therapeutics; Amgen; Vifor Pharma; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Carboplatin; Veliparib; Breast cancer; Hazard ratio; Metastatic breast cancer; Oncology; Population; Triple-negative breast cancer; Progression-free survival; Cancer; Chemotherapy; Confidence interval; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008396927,0.0008450953,0.001522867,0.0002543462,0.0002657528,0.001394436,0.0005782397,0.0006711534,0.003108179],"category_scores_gemma":[0.000665762,0.0003117595,0.001718695,0.0004392496,0.0005823755,0.0007440035,0.0003396871,0.002362496,0.0007547699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008971966,"about_ca_system_score_gemma":0.0008814252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001597623,"about_ca_topic_score_gemma":0.005886901,"domain_scores_codex":[0.9997377,0.00010212,0.00001231444,0.00005419794,0.00002636271,0.00006738267],"domain_scores_gemma":[0.9997587,0.00004969975,0.00004659931,0.00002329582,0.00001471618,0.0001070734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8227893,0.006030272,0.008782675,0.00139252,0.004831207,0.0001406745,0.0001780001,0.003791888,0.0130309,0.0006285414,0.008407557,0.1299964],"study_design_scores_gemma":[0.8529444,0.07903326,0.04411002,0.000276654,0.004679158,0.0004834249,0.0002444468,0.002799582,0.002438953,0.001692839,0.01121048,0.00008678746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815454,0.009579984,0.000316679,0.001044708,0.0002098391,0.0004576197,0.001998623,0.0001055503,0.004741651],"genre_scores_gemma":[0.9863384,0.00457756,0.0005956577,0.001219101,0.0001468454,0.0003358679,0.004105373,0.00004705734,0.002634205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003108179,"threshold_uncertainty_score":0.01039785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03757875422880337,"score_gpt":0.347691989660081,"score_spread":0.3101132354312776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}